Status:
COMPLETED
QT Variability Pre and Post Cardioversion
Lead Sponsor:
Vanderbilt University
Collaborating Sponsors:
National Institutes of Health (NIH)
Wake Forest University Health Sciences
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
21+ years
Brief Summary
The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.
Detailed Description
Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increase...
Eligibility Criteria
Inclusion
- At least 21 years of age
- Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center
Exclusion
- Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability
- Undergoing DC-Cardioversion for post-cardiac surgery
- Dual chamber pacemakers
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT00885391
Start Date
January 1 2007
End Date
March 1 2012
Last Update
December 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-0575